nach oben

Clinical Pharmacokinetics

Erschienen in:

01.05.2006 | Review Article

Hypericum Perforatum: A ‘Modern’ Herbal Antidepressant

Pharmacokinetics of Active Ingredients

verfasst von: Dr Mario Wurglics, Manfred Schubert-Zsilavecz

Erschienen in: Clinical Pharmacokinetics | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Hypericum perforatum (St John’s Wort [SJW]) counts among the most favourite herbal drugs, and is the only herbal alternative to classic synthetic antidepressants in the therapy of mild to moderate depression. Several clinical studies have been conducted to verify the effectiveness of ethanolic or methanolic extracts of SJW.

Alcoholic SJW extracts are a mixture of substances with widely varying physical and chemical properties and activities. Hyperforin, a phloroglucinol derivative, is the main source of pharmacological effects caused by the consumption of alcoholic extracts of SJW in the therapy of depression. However, several studies indicate that flavone derivatives, e.g. rutin, and also the naphthodianthrones hypericin and pseudohypericin, take part in the antidepressant efficacy.

In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce.

The hyperforin plasma concentration in humans was investigated in a small number of studies. The results of these studies indicate a relevant plasma concentration, comparable with that used in in vitro tests. Furthermore, hyperforin is the only ingredient of H. perforatum that could be determined in the brain of rodents after oral administration of alcoholic extracts.

The plasma concentrations of the hypericins were, compared with hyperforin, only one-tenth and, until now, the hypericins could not be found in the brain after oral administration of alcoholic H. perforatum extracts or pure hypericin.

Until now, the pharmacokinetic profile of the flavonoids in humans after oral administration of an alcoholic H. perforatum extract has been investigated in only one study. More data are available for rutin and the aglycone quercetin after administration of pure substances or other flavonoid sources.

The use of trade names is for product identification purposes only and does not imply endorsement.

WHO. Depression: what is depression [online]? Available from URL: http://www.who.int/mental_health/management/depression/definition/en/ [Accessed 2006 Feb 28]

Ayuso-Mateos JL, Vazquez-Barquero JL, Dowrick C, et al. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry 2001; 179: 308–16PubMed

Hale AS. ABC of mental health: depression. BMJ 1997; 315(7099): 43–6PubMed

Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry Suppl 2003; 183: 514–9

Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8–19PubMed

Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12(1): 19–29PubMed

Richelson E. Treatment of acute depression. Psychiatr Clin North Am 1993; 16(3): 461–78PubMed

Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med 1994; 36(9): 983–8PubMed

Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 511–27PubMed

10.

Müller WE. St. John’s Wort and its active principles in depression and anxiety. Basel: Birkhäuser, 2005

11.

Kommission E. Monographie: Hyperici herba (Johanniskraut). Bundesanzeiger 1984: 228

12.

Kasper S. Hypericum perforatum: a review of clinical studies. Pharmacopsychiatry 2001; 34 Suppl. 1: S51–5PubMed

13.

Berner M, Riemann D, Berger M. The Efficacy of SJW extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression [abstract]. Eur Arch Psychiatry Clin Neurosci 2002; 252 Suppl. 1: 56

14.

Laakmann G, Schule C, Baghai T, et al. St. John’s Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 Suppl. 1: 54–9PubMed

15.

Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John’s Wort in major depression: a randomized controlled trial. JAMA 2001; 285(15): 1978–86PubMed

16.

Linde K, Berner M, Egger M, et al. St John’s Wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 2005; 186: 99–107PubMed

17.

Schwabe U, Paffrath D. Arzneiverordnungs report 2003. Berlin: Springer-Verlag, 2004

18.

Capasso F, Gaginella TS, Grandolini G, et al. Phytotherapy: a quick reference to herbal medicine. Berlin: Springer-Verlag, 2003

19.

St. John’s Wort. European Pharmacopoeia 2003; 4 Suppl. 4.5: 2157–8

20.

European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products [online]. Available from URL: http://www.emea.eu.int/pdfs/human/qwp/281900en.pdf [Accessed 2006 Feb 28]

21.

Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin. Planta Medica 1984; 50(3): 272–4PubMed

22.

Nöldner M, Schotz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Medica 2002; 68(7): 577–80PubMed

23.

Melzer R, Fricke U, Holzl J. Vasoactive properties of procyanidins from Hypericum perforatum L. in isolated porcine coronary arteries. Arzneimittel Forschung 1991; 41(5): 481–3PubMed

24.

Barnes J, Anderson LA, Phillipson JD. St John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53(5): 583–600PubMed

25.

Gambarana C, Tolu PL, Masi F, et al. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry 2001; 34 Suppl. 1: S42–4PubMed

26.

Schulte-Lobbert S, Holoubek G, Muller WE, et al. Comparison of the synaptosomal uptake inhibition of serotonin by St John’s Wort products. J Pharm Pharmacol 2004; 56(6): 813–8PubMed

27.

Muller WE, Rolli M, Schafer C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl. 2: 102–7PubMed

28.

Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63(6): 499–510PubMed

29.

Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001; 68(14): 1593–605PubMed

30.

Muller WE, Singer A, Wonnemann M. Hyperforin: antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34 Suppl. 1: S98–102PubMed

31.

Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na^+l. J Pharmacol Exp Ther 1999; 290(3): 1363–8PubMed

32.

Wonnemann M, Singer A, Muller WE. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John’s Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000; 23(2): 188–97PubMed

33.

Gobbi M, Valle FD, Ciapparelli C, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1999; 360(3): 262–9PubMed

34.

Gobbi M, Moia M, Pirona L, et al. In vitro binding studies with two Hypericum perforatum extracts hyperforin, hypericin and biapigenin on 5-HT6, 5-HT7, GABA (A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001; 34 Suppl. 1: S45–8PubMed

35.

Roz N, Rehavi M. Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci 2003; 73(4): 461–70PubMed

36.

Roz N, Mazur Y, Hirshfeld A, et al. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci 2002; 71(19): 2227–37PubMed

37.

Eckert GP, Keller JH, Jourdan C, et al. Hyperforin modifies neuronal membrane properties in vitro. Neurosci Lett 2004; 367(2): 139–43PubMed

38.

Treiber K, Singer A, Müller WE. Activation of nonselective cation channels by hyperforin: a novel mechanism of antidepressant activity [abstract]. Soc Neurosci 2003; 29: 851

39.

Calapai G, Crupi A, Firenzuoli F, et al. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 1999; 51(6): 723–8PubMed

40.

Yu PH. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 2000; 33(2): 60–5PubMed

41.

Serdarevic N, Eckert GP, Muller WE. The effects of extracts from St. John’s Wort and Kava Kava on brain neurotransmitter levels in the mouse. Pharmacopsychiatry 2001; 34 Suppl. 1: S134–6PubMed

42.

Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s Wort. Lancet 2000; 355(9203): 548–9PubMed

43.

Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John’s Wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94(16): 1247–9PubMed

44.

Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355(9198): 134–8PubMed

45.

Ernst E. St John’s Wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137(3): 316–9PubMed

46.

Ernst E. Second thoughts about safety of St John’s Wort. Lancet 1999; 354(9195): 2014–6PubMed

47.

Ernst E, Rand JI, Barnes J, et al. Adverse effects profile of the herbal antidepressant St. John’s Wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54(8): 589–94PubMed

48.

Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John’s Wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76(4): 330–40PubMed

49.

Wentworth JM, Agostini M, Love J, et al. St John’s Wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166(3): R11–6PubMed

50.

Watkins RE, Maglich JM, Moore LB, et al. 2.1 A crystal structure of human PXR in complex with the St. John’s Wort compound hyperforin. Biochemistry 2003; 42(6): 1430–8PubMed

51.

Moore LB, Goodwin B, Jones SA, et al. St. John’s Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97(13): 7500–2PubMed

52.

Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St. John’s Wort and theophylline. Ann Pharmacother 1999; 33(4): 502PubMed

53.

Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73(1): 67–74PubMed

54.

Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290(11): 1500–4PubMed

55.

Izzo AA. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42(3): 139–48PubMed

56.

Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John’s Wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32(5): 512–8PubMed

57.

Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John’s Wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55(1): 112–3PubMed

58.

Henderson L, Yue QY, Bergquist C, et al. St John’s Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54(4): 349–56PubMed

59.

Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John’ s Wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56(6): 683–90PubMed

60.

Hall SD, Wang Z, Huang SM, et al. The interaction between St John’s Wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74(6): 525–35PubMed

61.

Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s Wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66(4): 338–45PubMed

62.

Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St John’s Wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004; 56(1): 123–8PubMed

63.

Wang Z, Hamman MA, Huang SM, et al. Effect of St John’s Wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71(6): 414–20PubMed

64.

Bodo A, Bakos E, Szeri F, et al. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003; 140–141: 133–43PubMed

65.

Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68(6): 598–604PubMed

66.

Mannel M. Drug interactions with St John’s Wort: mechanisms and clinical implications. Drug Saf 2004; 27(11): 773–97PubMed

67.

Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30 Suppl. 2: 129–34PubMed

68.

Schulte-Lobbert S, Westerhoff K, Wilke A, et al. Development of a high-performance-liquid-chromatographic method for the determination of biapigenin in biorelevant media. J Pharm Biomed Anal 2003; 33(1): 53–60PubMed

69.

Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349(9053): 699PubMed

70.

Yochum L, Kushi LH, Meyer K, et al. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women [published erratum appears in Am J Epidemiol 1999 Aug 15; 150 (4): 432]. Am J Epidemiol 1999; 149(10): 943–9PubMed

71.

Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II): a randomized, double-blind, placebo-controlled trial. Arzneimittel Forschung 2000; 50(2): 109–17PubMed

72.

Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur J Clin Pharmacol 1996; 50(6): 443–7PubMed

73.

Demisch L, Hölzl J, Gollnik B, et al. Identification of selective MAO-Typ A inhibition of Hypericum perforatum L [abstract]. Pharmacopsychiatry 1989; 22: 194

74.

Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: S54–6PubMed

75.

Cracchiolo C. Pharmacology of St. John’s Wort: botanical and chemical aspects. Sci Rev Alt Med 1998; 2: 29–35

76.

Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30 Suppl. 2: 108–12PubMed

77.

Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John’s Wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl) 2002; 162(2): 193–202

78.

Butterweck V, Jurgenliemk G, Nahrstedt A, et al. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 2000; 66(1): 3–6PubMed

79.

Porsolt RD. Animal model of depression. Biomedicine 1979; 30(3): 139–40PubMed

80.

Nöldner M. Behandlung von depressiven Patienten in der täglichen Praxis — Stellenwert von Johanniskraut. Neu-Isenburg: LinguaMed Verlags-GmbH, 2001

81.

Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 2001; 34 Suppl. 1: S2–7PubMed

82.

Butterweck V, Hegger M, Winterhoff H. Flavonoids of St. John’s Wort reduce HPA axis function in the rat. Planta Med 2004; 70(10): 1008–11PubMed

83.

Rubin RT, Phillips JJ, McCracken JT, et al. Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. Biol Psychiatry 1996; 40(2): 89–97PubMed

84.

Rubin RT, Phillips JJ, Sadow TF, et al. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995; 52(3): 213–8PubMed

85.

Holsboer F, Benkert O. Neuroendocrinologic and endocrinologic research in depressive patients [in German]. Nervenarzt 1985; 56(1): 1–11PubMed

86.

Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness: normalisation of test result compared with clinical improvement. J Affect Disord 1982; 4(2): 93–101PubMed

87.

Baureithel KH, Buter KB, Engesser A, et al. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 1997; 72(3): 153–7PubMed

88.

Butterweck V, Lieflander-Wulf U, Winterhoff H, et al. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69(3): 189–92PubMed

89.

Butterweck V, Bockers T, Korte B, et al. Long-term effects of St. John’s Wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 2002; 930(1–2): 21–9PubMed

90.

Butterweck V, Winterhoff H, Herkenham M. St John’s Wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 2001; 6(5): 547–64PubMed

91.

Butterweck V, Petereit F, Winterhoff H, et al. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64(4): 291–4PubMed

92.

Brockmöller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl. 2: 94–101PubMed

93.

Agostinis P, Vantieghem A, Merlevede W, et al. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002; 34(3): 221–41PubMed

94.

Lenard J, Rabson A, Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A 1993; 90(1): 158–62PubMed

95.

Andersen DO, Weber ND, Wood SG, et al. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral Res 1991; 16(2): 185–96PubMed

96.

Hänsel R, Keller K, Rimpler H, et al. Hager’s Handbuch der Pharmazeutischen Praxis. Berlin: Srpinger-Verlag, 1993

97.

Hölzl J, Sattler S, Schutt H. Johanniskraut: eine Alternative zu synthetischen Antidepressiva? Pharmazeutische Zeitung 1994; 139: 3959–77

98.

Erdelmeier CA. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31 Suppl. 1: 2–6PubMed

99.

Ostrowski E. Untersuchung zur Analytik, 14C-Markierung und Pharmakokinetik phenolischer Inhaltsstoffe von Hypericum perforatum L. Marburg: University of Marburg, 1988

100.

Biber A, Fischer H, Romer A, et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31 Suppl. 1: 36–43PubMed

101.

Franklin M, Chi J, McGavin C, et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999; 46(4): 581–4PubMed

102.

Agrosi M, Mischiatti S, Harrasser PC, et al. Oral bioavailability of active principles from herbal products in humans: a study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 2000; 7(6): 455–62PubMed

103.

Cui Y, Gurley B, Ang CY, et al. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 780(1): 129–35PubMed

104.

Schulz HU, Schurer M, Bassler D, et al. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittel Forschung 2005; 55(1): 15–22PubMed

105.

Wurglics M, Westerhoff K, Kaunzinger A, et al. Batch-to-batch reproducibility of St. John’s Wort preparations. Pharmacopsychiatry 2001; 34 Suppl. 1: S152–6PubMed

106.

Wonnemann M, Singer A, Siebert B, et al. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John’s Wort. Pharmacopsychiatry 2001; 34 Suppl. 1: S148–51PubMed

107.

Cervo L, Rozio M, Ekalle-Soppo CB, et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 2002; 164(4): 423–8PubMed

108.

Keller JH, Karas M, Muller WE, et al. Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2003; 75(22): 6084–8PubMed

109.

Liebes L, Mazur Y, Freeman D, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991; 195(1): 77–85PubMed

110.

Bauer S, Stornier E, Graubaum HJ, et al. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 765(1): 29–35PubMed

111.

Pirker R, Huck CW, Bonn GK. Simultaneous determination of hypericin and hyperforin in human plasma and serum using liquid-liquid extraction, high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2002; 777(1–2): 147–53

112.

Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40(9): 2087–93PubMed

113.

Staffeldt B, Kerb R, Brockmoller J, et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriate Psychiatry Neurol 1994; 7 Suppl. 1: S47–53

114.

Weiser D. Pharmakokinetik von Hypericin nach der oralen Einnahme des Johanniskraut-Extrakte LI160. Nervenheilkunde 1991; 10: 318–9

115.

Fox E, Murphy RF, McCully CL, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 2001; 47(1): 41–4PubMed

116.

Hollman PC, de Vries JH, van Leeuwen SD, et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62(6): 1276–82PubMed

117.

Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 1997; 418(1–2): 152–6PubMed

118.

Hollman PC, Bijsman MN, van Gameren Y, et al. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic Res 1999; 31(6): 569–73PubMed

119.

Cermak R, Landgraf S, Wolffram S. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J Nutr 2003; 133(9): 2802–7PubMed

120.

Wolffram S, Block M, Ader P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J Nutr 2002; 132(4): 630–5PubMed

121.

Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41(5): 492–9PubMed

122.

Day AJ, Mellon F, Barron D, et al. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 2001; 35(6): 941–52PubMed

123.

Ishii K, Furata T, Kasuya Y. Determination of rutin in human plasma by high-performance liquid chromatography utilizing solid-phase extraction and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 759(1): 161–8PubMed

124.

Manach C, Morand C, Demigne C, et al. Bioavailability of ratin and quercetin in rats. FEBS Lett 1997; 409(1): 12–6PubMed

125.

O’Leary KA, Day AJ, Needs PW, et al. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 2003; 65(3): 479–91PubMed

126.

Graefe EU, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther 1999; 37(5): 219–33PubMed

127.

Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000; 56(8): 545–53PubMed

128.

Erlund I, Alfthan G, Siren H, et al. Validated method for the quantitation of quercetin from human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1999; 727(1–2): 179–89PubMed

129.

Juergenliemk G, Boje K, Huewel S, et al. In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med 2003; 69(11): 1013–7PubMed

130.

Gutmann H, Braggisser R, Schaffner W, et al. Transport of amentoflavone across the blood-brain barrier in vitro. Planta Med 2002; 68(9): 804–7PubMed

Titel: Hypericum Perforatum: A ‘Modern’ Herbal Antidepressant
Pharmacokinetics of Active Ingredients
verfasst von: Dr Mario Wurglics
Manfred Schubert-Zsilavecz
Publikationsdatum: 01.05.2006
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 5/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645050-00002

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Hypericum Perforatum: A ‘Modern’ Herbal Antidepressant

Pharmacokinetics of Active Ingredients

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

The Influence of Cardiovascular Physiology on Dose/Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Relationships

Population Pharmacokinetics of Ceftriaxone and Pharmacodynamic Considerations in Haemodialysed Patients

Clinical Pharmacokinetics of Ranolazine

An Extended Terminal Half-Life for Darbepoetin Alfa